Modelling efficacy of natalizumab in patients who switch from standard interval dosing (SID) to extended interval dosing (EID)

被引：0
|
作者：
Chang, I. [1 ]
Muralidharan, K. [1 ]
Campbell, N. [1 ]
Ho, P. -R. [1 ]
机构：
[1] Biogen, Cambridge, MA USA
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2019年 / 26卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
EPO1223
引用
下载
收藏
页码：480 / 480
页数：1
相关论文
共 50 条
  • [41] Effectiveness and safety profile of the natalizumab extended interval dosing in a spanish cohort
    Costa-Frossard, L.
    Sainz De La Maza, S.
    Monreal, E.
    Gomez Lopez, A.
    Fernandez-Velasco, J. I.
    Walo Delgado, P.
    Espino, M.
    Villarrubia, N.
    Masjuan, J.
    Villar, L. M.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 278 - 278
  • [42] Natalizumab extended-interval dosing in a real-life setting
    Jeantin, Lina
    de la Motte, Marine Boudot
    Deschamps, Romain
    Gueguen, Antoine
    Gout, Olivier
    Lecler, Augustin
    Papeix, Caroline
    Bensa, Caroline
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2023, 450
  • [43] Personalized extended interval dosing of natalizumab in MS A prospective multicenter trial
    van Kempen, Zoe L. E.
    Hoogervorst, Erwin L. J.
    Wattjes, Mike P.
    Kalkers, Nynke F.
    Mostert, Jop P.
    Lissenberg-Witte, Birgit I.
    de Vries, Annick
    ten Brinke, Anja
    van Oosten, Bob W.
    Barkhof, Frederik
    Teunissen, Charlotte E.
    Uitdehaag, Bernard M. J.
    Rispens, Theo
    Killestein, Joep
    NEUROLOGY, 2020, 95 (06) : E745 - E754
  • [44] Exploratory PML risk assessment on Extended Interval Natalizumab Dosing.
    Ryerson, Lana Zhovtis
    Foley, John
    Kister, Ilya
    Frohman, Teresa
    Pandey, Krupa
    Lu, Xiaochun
    Goldberg, Judith
    Zuniga-Estrada, Guadalupe
    Hoyt, Tammy
    Jacob, April
    Bacon, Tamar
    Major, Eugene
    Frohman, Elliot
    NEUROLOGY, 2017, 88
  • [45] Extended dosing interval reduces risk of natalizumab-related PML
    Reactions Weekly, 2019, 1772 (1) : 9 - 9
  • [46] Real world effectiveness of Natalizumab extended interval dosing in a French cohort
    Pelle, J.
    Briant, A.
    Lebrun-Frenay, C.
    Cohen, M.
    Mondot, L.
    De Seze, J.
    Bigaut, K.
    Collongues, N.
    Kremer, L.
    Ricard, D.
    Bompaire, F.
    Sallansonnet-Froment, M.
    Ohlmann, C.
    Ciron, J.
    Biotti, D.
    Pignolet, B.
    Parienti, J.
    Defer, G.
    EUROPEAN JOURNAL OF NEUROLOGY, 2022, 29 : 207 - 207
  • [47] Mri activity and extended interval of natalizumab dosing: a multicenter italian study
    Clerico, M.
    De Mercanti, S. F.
    Signori, A.
    Iudicello, M.
    Cordioli, C.
    Signoriello, E.
    Lus, G.
    Bonavita, S.
    Lavorgna, L.
    Maniscalco, G. T.
    Curti, E.
    Lorefice, L.
    Cocco, E.
    Nociti, V.
    Mirabella, M.
    Baroncini, D.
    Mataluni, G.
    Landi, D.
    Petruzzo, M.
    Lanzillo, R.
    Gandoglia, I.
    Laroni, A.
    Frangiamore, R.
    Sartori, A.
    Cavalla, P.
    Costantini, G.
    Sormani, M. P.
    Capra, R.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 538 - 538
  • [48] Risk of natalizumab-associated PML in patients with MS is reduced with extended interval dosing
    Ryerson, Lana Zhovtis
    Foley, John
    Chang, Ih
    Kister, Ilya
    Cutter, Gary
    Metzger, Ryan R.
    Goldberg, Judith D.
    Li, Xiaochun
    Riddle, Evan
    Smirnakis, Karen
    Kasliwal, Rachna
    Ren, Zheng
    Hotermans, Christophe
    Ho, Pei-Ran
    Campbell, Nolan
    NEUROLOGY, 2019, 93 (15) : E1452 - E1462
  • [49] Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
    Zid, Yasmin
    Robertson, Neil P.
    JOURNAL OF NEUROLOGY, 2024, 271 (4) : 2141 - 2143
  • [50] Extended interval dosing strategies in multiple sclerosis: insights from natalizumab and ocrelizumab trials
    Yasmin Zid
    Neil P. Robertson
    Journal of Neurology, 2024, 271 : 2141 - 2143
12345